中国制药行业进入分化期,创新药将成为企业突围核心竞争力

制药网
19 May

【制药网 市场分析】近期,2025年一季度上市企业的业绩单都已接踵而来。从整体来看,受政策调整、市场竞争与创新转型的多重影响,国内药企发展已逐渐呈现出分化趋势。其中,头部企业凭借创新药布局保持增长,而部分传统药企则已开始面临收入下滑的挑战。5月13日,诺诚健华公布的一季度报显示,公司报告期内实现营业收入3.81亿元,同比增长129.92%,归母净利润1797万元。这是诺诚健华自2022年登陆A股...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10